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Recruitment of mononuclear phagocytes from the blood into
tissues is considered to be a crucial process during inflammatory
reactions, wound healing and tumor growth. Macrophages are
known to reveal high plasticity and may change under the influ-
ence of microenvironment. The aim of the study was to evaluate
the changes of macrophage functional activity under the influ-
ence of Vascular endothelial growth factor (VEGF) in vitro. This
factor is known to be the main angiogenic factor but also pos-
sesses several immunomodulatory properties. Here we report
that VEGF revealed a dose-dependent effects on cultured freshly
isolated murine resident peritoneal macrophages: modulated
iNOS mRNA expression, nitroxide and superoxide anion produc-
tion, decreased 5
0
-nucleotidase (5
0
-N) activity, but had no influ-
ence on fluid-phase pinocytosis. Moreover, VEGF increased
expression of its own mRNA via autocrine pathway as well as of
VEGF protein expression. VEGF also induced up-regulation of
extracellular matrix protein thrombospondin-1 (TSP-1) mRNA,
which is considered as a part of macrophage activation pheno-
type. Production of cytokines and chemokines by macrophages
was screened with the help of Multi- analyte ELISArray kits. It
was found that incubation of macrophages in the presence of
VEGF increased the production of angiogenic cytokines – TNF-a
and IL-6 as well as several monocyte and leukocyte chemoattrac-
tants such as MCP-1, RANTES and MIP-1b. Therefore, we suggest
that locally established VEGF gradient may influence inflamma-
tory phenotype of tissue macrophages as well as potentiate their
pro-angiogenic properties. This work was supported by Russian
Foundation for Basic Research – Russia, Grant No. 15-04-06150.
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Epigenetics investigates mechanisms that control inheritance
of gene expression program during somatic cell divisions. These
mechanisms include regulation by DNA methylation, histone
post-translational modifications and nucleosome positioning,
functioning of regulatory non-coding RNAs, control of alternative
splicing of mRNA precursors and high-order chromatin organiza-
tion. Genome-wide loss of epigenetic stability and increased
epigenetic plasticity are common features of all tumor types. In
normal tissues epigenetic plasticity allow cells to response on
environment signals. Thus, in tumor cells its constitutive activa-
tion leads to epigenetic heterogeneity that are the additional
hallmark of the most of the classical cancers. Cervical cancers
are one of the most interesting models for the analysis of the role
of epigenetic changes in tumor progression. These types of
tumors are associated with infection of human papilloma viruses
of so-called high-risk group (HR-HPV) and characterized by
well-defined stages of malignant conversion from intraepithelial
neoplasias to carcinomas. The viral DNA can persist in episomal
form or integrates into the host-cell genome.
Cellular genomes encode genetic information in their linear
sequence, but appropriate gene expression requires chromo-
somes to fold into dynamic complex three-dimensional
structures. Scaffold/matrix attachment regions (S/MARs) are
specialized genomic DNA sequences that take part in organiza-
tion of these structures. We demonstrated that methylation of
S/MARs was required for their attachment to nuclear matrix
and that methylation status of S/MARs was changed in cervical
cancer cell compared to normal cells.
DNA methylation plays an important role in the regulation of
gene expression. We found that methylation of the regulatory
sequences in the HPV16 genome specifically changes in
transformed compared to the normal cervical epithelial cells.
Next, we showed that methylation of the transcription factor
binding sites modulates the viral oncogene expression. These
data suggest that the HPV16 genome methylation may represent
an important mechanism that initiates the development of
HPV-associated tumors.
Using next generation sequencing, we identified pattern of
differentially expressed microRNAs in clinical samples of the
cervical lesions. We confirmed expression of microRNAs that
have been described previously as well as identified new
microRNAs that can be potentially involved in the development
and progression of cervical cancer. Spectrum of differentially
expressed microRNAs includes microRNAs targeting tumor-
suppressor genes as well as oncogenes.
Telomerase is a key regulator of cell proliferation. This enzyme
is silent in normal cells and activated in most of the tumors. Few
forms of RNA (hTERT), encoded by telomerase gene were detected
in different tumor cells and among them three forms (alfa, beta
and gamma) are most well pronounced. We found that in cervical
tumors expression of all three forms are significantly increased.
In some cases, we also observe higher level of hTERT expression
in neighboring ‘‘normal tissue”. The correlation between
expression levels of these three forms varied on different stages
of the disease (three stages on intraepithelial neoplasias and
carcinomas). The function of these three hTERT forms is still
not well understood.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.044
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The most effective method in treatment of inoperable cancer
is currently miniallogeneic transplantation. This type of treat-
ment focuses on reaction of ‘‘graft-versus-tumor”. According to
preliminary data, such treatment leads to long-term remission
in patients with metastatic cancer, who did not respond to
previous therapy. Anti-tumor immune response after transplant
may be extended or enhanced by additional infusion of donor
lymphocytes. Research has shown that introduction of donor
lymphocytes achieves complete remission of the tumor, even in
case of relapse after allogeneic transplantation from the same
donor, but these effects are unstable and not so long because of
rapid elimination of donor lymphocytes [1]. The main problem
is the preservation of cell transplantation viability and functional
activity of the cells in patient’s body, and protecting them
from recipient’s immune system. In recent years, most suitable
for this purpose are the three-dimensional porous biomaterials
(3D-scaffold).
Specific pore space does not allow immunity effectors
quickly destroy the cells in scaffold [2,3]. Research Institute of
medical materials and implants with shape memory at the
Tomsk State University created a porous-permeable incubators
(scaffold) of TiNi-based shape memory alloy (TiNi). The material
has unique properties: permeable porous structure by open
interconnected pores, characterized by high degree of wettabil-
ity with tissue media and nanoporous inner surface of the pore
walls, exhibits high adhesion to various cell types, so all
mentioned meet requirements of the bio-chemical and bio-
mechanical compatibility. Porous TiNi-based scaffolds allow
continually to keep the functionality cells and prolong their
action [4,5].
The purpose of this study was to investigate possibility of
modulation of antitumor response in allogeneic bone marrow
transplantation in porous-permeable incubator of TiNi.
Results: Intraperitoneal injection of allogeneic bone marrow
(BM) reduces metastasis by 30% and has easy 10%-antitumor
effect. At the same time, the implantation of bone marrow cells
on incubator of TiNi (BM + TiNi) leads to more pronounced antitu-
mor (25%) and significant antimetastatic effects (45%). Life span
of animals with tumors and implanted bone marrow cells on
incubator TiNi is increased by 60%
Since bone marrow cells do not have direct antiproliferative
effect on tumor target cells in vitro, it is assumed that one of
the mechanisms effecting the bone marrow transplantation on
neoplastic process is the stimulation of endogenous effectors of
antitumor immunity.
The study of morphological parameters immunocompetent
organs showed that administration of allogeneic bone marrow
cells can reduce thymic regression, decrease splenomegaly at ani-
mals with transplanted tumors.
Conclusion: Allogeneic transplantation of bone marrow cells
on porous incubator was shown to prolong and enhance antitu-
mor and antimetastatic action compared to injecting the cells.
This effect is directly due to the stimulation of antitumor
immunity, that is described by the study of immunity factors.
The results show perspectives of porous TiNi-based scaffolds in
complex treatment of neoplastic diseases.
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Background: Tumor cells in chronic lymphocytic leukemia
(CLL) usually have the ‘‘classic” immunophenotype CD19+,
CD5+, CD23+, SmIgdim, CD20dim, FMC7-, CD79b-/dim, CD22-/dim.
However, sometimes some deviations in antigenic profile CLL cells
are observed such as enhanced expression of CD79b, CD22, SmIg
and CD20. The most frequent cytogenetic abnormalities in CLL are
trisomy 12 and deletions of 13q14, 13q34, 6q, 11q, and 17p. It is
noted that immunophenotypic deviations in CLL often correlate
with some of these cytogenetic anomalies. The investigation of
the links between the antigens expression and caryotype of CLL
cells leads to differential diagnostics and prognosis in CLL. The goal
of the investigation is search for the links between immunopheno-
typic characteristics of CLL cells and their karyotype.
Material and methods: Bone marrow and blood cells from 35
CLL patients are investigated. Immunophenotyping was made
using flow cytometer ‘‘Cytomics F500” (Beckman Coulter) with
the use of monoclonal antibodies CD3/CD19/CD45, SmIgj
SmIgk/CD19, CD5/CD23/CD19, FMC7/CD38/CD19, CD22/CD79b/
CD19, CD10/CD20/CD19. For karyotype determination the
standard cytogenetic methods and FISH were used.
Results: The most frequent deletion in CLL patients was del(13)
(q14.3), it was sometimes observed together with (13)(q34) and
was found in18 patients (51% of all examined patients). 56%
(10/18) of patients in this group had CLL cells phenotype CD19+,
CD5+, CD23+, SmIgdim, CD20dim, FMC7-, CD79b-, CD22- and
CD38-. Weak (dim) expression of CD79b antigen (in 24–92% of
cells) was found in 39% (7/18) of patients with del(13)(q14.3),
and expression of CD38 (in 22–86% of cells) – in 17% (3/18).
The same phenotype was observed in 2 patients (6%) having
only del(13)(q34), in one patient (3%) with (13)(q34) trisomy and
in 6 patients (17%) with normal karyotype 46, XY.
Trisomy 12 was found in 14% (5/35) of explored CLL patients.
The immunophenotype of CLL cells in this group was very differ-
ent with the previous group. All patients (100%) with trisomy 12
had CLL cells with expression of CD79b (94.2% of cells), CD22
(54–94.6% of cells), CD38 (31.1–99.3% of cells). Additionally 2 of 5
patients (40%) had CLL cells with more bright (dim to mod)
CD20 expression and 1 patient (20%) had cells with bright
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